Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine

Abstract Objective Despite the high vaccine efficacy of mRNA COVID‐19 vaccines, there are individuals who developed excessive reactogenic and/or allergic responses after the first mRNA dose and were considered ineligible for further mRNA doses. CoronaVac, an inactivated SARS‐CoV‐2 vaccine, is recomm...

Full description

Bibliographic Details

Published in:	Clinical & Translational Immunology
Main Authors:	Yun Shan Goh, Siew‐Wai Fong, Angeline Rouers, Zi Wei Chang, Matthew Zirui Tay, Jean‐Marc Chavatte, Nicole Ziyi Zhuo, Pei Xiang Hor, Chiew Yee Loh, Yuling Huang, Joel Xu En Wong, Yong Jie Tan, Daniel Rui Xiang Lim, Bei Wang, Eve Zi Xian Ngoh, Siti Nazihah Mohd Salleh, Raphael Tze Chuen Lee, Surinder Pada, Louisa Jin Sun, Desmond Luan Seng Ong, Jyoti Somani, Eng Sing Lee, NCID Study Group, COVID‐19 Study Group, Sebastian Maurer‐Stroh, Cheng‐I Wang, Yee‐Sin Leo, Raymond TP Lin, Ee Chee Ren, David C Lye, Barnaby Edward Young, Poh Lian Lim, Lisa FP Ng, Laurent Renia
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Subjects:	Allergic Antibodies B cells CoronaVac COVID‐19 Delta
Online Access:	https://doi.org/10.1002/cti2.1403